Literature DB >> 2730417

The anti-tumor effect of in vitro tumor-stimulated autologous peripheral blood lymphocytes measured by the subrenal capsule assay.

C Kürten1, R Kau, H Kumazawa, P Koldovsky.   

Abstract

Lymphokine-activated killer cells (LAK) are able to kill natural killer (NK)-resistant fresh bioptic tumor cells. We have tried to increase the antitumor activity of peripheral blood lymphocytes by the simultaneous stimulation with interleukin-2 and autologous tumor extract (TE). The influence of LAK cells and LAK cells stimulated with TE was compared in the subrenal capsule assay in nude mice. Experiments were performed with eight head and neck tumors following their surgical extirpation. The tumors were first grown in the renal capsule space while lymphocytes were being stimulated in vitro. Following this, the lymphocytes were injected into the growing tumors. The autologous TE-stimulated LAK cells were more effective in treating tumors than were the LAK cells. Tumors regressed in some cases so treated, a finding which was never observed with LAK cells alone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2730417     DOI: 10.1007/bf00457464

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  13 in total

1.  Stimulation of peripheral blood lymphocytes with autologous tumor and serum-derived fractions from patients with laryngeal carcinomas.

Authors:  P Koldovsky; U Koldovsky; J Ebbers; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

3.  Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.

Authors:  M T Lotze; S A Rosenberg
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

4.  Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes.

Authors:  F Vánky; E Klein
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

5.  Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays.

Authors:  B M Vose; W White
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.

Authors:  E A Grimm; D J Wilson
Journal:  Cell Immunol       Date:  1985-09       Impact factor: 4.868

7.  Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

8.  Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice.

Authors:  A E Bogden; P M Haskell; D J LePage; D E Kelton; W R Cobb; H J Esber
Journal:  Exp Cell Biol       Date:  1979

9.  Quantitation of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site.

Authors:  B M Vose
Journal:  Int J Cancer       Date:  1982-08-15       Impact factor: 7.396

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  1 in total

1.  Influence of LAK cells on expression of HLA-DR antigen on laryngeal carcinoma cell line in new culture systems.

Authors:  H Kumazawa; T Kumazawa; T Tachikawa; S Sai; T Yamashita; K Kawamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.